0.89
+0.0203(+2.34%)
Currency In USD
Address
111 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 881 6500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
269
First IPO Date
September 27, 2018
| Name | Title | Pay | Year Born |
| Ms. Jane Chung R.Ph. | Chief Executive Officer & Director | 820,000 | 1971 |
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer | 575,833 | 1963 |
| Mr. Edward C. Albini M.B.A | Chief Financial Officer & Secretary | 629,660 | 1958 |
| Dr. Barbara Leyman Ph.D. | Chief Business Officer | 0 | 1970 |
| Ms. Regina Cheng | Vice President & Controller | 0 | N/A |
| Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer | 0 | 1962 |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder | 0 | N/A |
| Mr. David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel | 0 | N/A |
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.